Suppr超能文献

格雷夫斯病低剂量¹³¹I补偿治疗的长期随访研究

Long-term follow-up study of compensated low-dose 131I therapy for Graves' disease.

作者信息

Sridama V, McCormick M, Kaplan E L, Fauchet R, DeGroot L J

出版信息

N Engl J Med. 1984 Aug 16;311(7):426-32. doi: 10.1056/NEJM198408163110702.

Abstract

We treated 187 patients who had Graves' disease with low-dose radioactive iodide (131I), using a protocol that included a compensation for thyroid size. The incidence of early hypothyroidism (12 per cent) was acceptably low in the first year after 131I treatment, but we found a cumulative high incidence (up to 76 per cent) at the end of the 11th year. In contrast, the incidence of permanent hypothyroidism was relatively stable in 166 surgically treated patients, increasing from 19 to 27 per cent at the end of 11 years. Among 122 medically treated patients, only 40 per cent entered remission, and hypothyroidism developed in 2 per cent during the same period of follow-up. The long-term incidence of hypothyroidism in our patients treated with low-dose 131I therapy was much higher than that found in earlier studies using a comparable dose. Our study suggests that it will be difficult to modify therapy with 131I alone to produce both early control of thyrotoxicosis and a low incidence of hypothyroidism.

摘要

我们采用一种包含甲状腺大小补偿的方案,用低剂量放射性碘(¹³¹I)治疗了187例格雷夫斯病患者。¹³¹I治疗后第一年,早期甲状腺功能减退的发生率(12%)较低,尚属可接受范围,但我们发现在第11年末累积发生率较高(高达76%)。相比之下,166例接受手术治疗的患者中,永久性甲状腺功能减退的发生率相对稳定,11年末从19%增至27%。在122例接受药物治疗的患者中,只有40%进入缓解期,且在相同随访期内有2%发生甲状腺功能减退。我们采用低剂量¹³¹I治疗的患者中,甲状腺功能减退的长期发生率远高于早期使用类似剂量的研究。我们的研究表明,仅用¹³¹I调整治疗方案,很难在早期控制甲状腺毒症的同时降低甲状腺功能减退的发生率。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验